<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294043</url>
  </required_header>
  <id_info>
    <org_study_id>ABATE-IP-18</org_study_id>
    <secondary_id>R01FD006848</secondary_id>
    <nct_id>NCT04294043</nct_id>
  </id_info>
  <brief_title>IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)</brief_title>
  <acronym>ABATE</acronym>
  <official_title>A Phase 1b, Multi-center Study of Intravenous (IV) Gallium Nitrate in Patients With Cystic Fibrosis (CF) Who Are Colonized With Nontuberculous Mycobacteria (NTM) (The ABATE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chris Goss</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of two 5-day infusion&#xD;
      cycles of IV gallium in adult patients with CF who are infected with NTM.&#xD;
&#xD;
      Funding Source - FDA OOPD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter open-label study in adults with CF who are colonized with&#xD;
      M. avium complex and/or M. abscessus complex.&#xD;
&#xD;
      Subjects will receive two 5-day infusion cycles of IV gallium. The study will evaluate the&#xD;
      safety and antimycobacterial effect of two 5-day infusions of IV gallium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events of Special Interest</measure>
    <time_frame>Baseline to Day 57</time_frame>
    <description>Proportion of patients experiencing one or more Adverse Events of Special Interest (AESI). AESIs include the occurrence of either (1) a serious adverse event (SAE) of grade 3 or higher including hospitalizations or (2) study drug discontinuation because of an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant abnormal laboratory measures. (safety)</measure>
    <time_frame>Baseline to Day 57</time_frame>
    <description>Proportion of patients experiencing clinically significant abnormal laboratory measures. Clinically significant abnormal laboratory measures are identified by the site investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTM clearance (efficacy)</measure>
    <time_frame>Day 6 to Day 111</time_frame>
    <description>Proportion of subjects who were NTM culture positive at baseline and have at least 2 sequential negative NTM cultures between visits 2 (Day 6) and 7 (Day 111). Those negative cultures must be at least 2 weeks apart.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Nontuberculous Mycobacterium Infection</condition>
  <arm_group>
    <arm_group_label>Infusion of IV Gallium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium nitrate</intervention_name>
    <description>Study subjects will receive an infusion of gallium nitrate.</description>
    <arm_group_label>Infusion of IV Gallium</arm_group_label>
    <other_name>Ga</other_name>
    <other_name>GaN3O9</other_name>
    <other_name>IV gallium</other_name>
    <other_name>ganite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained from subject or subject's legal representative&#xD;
&#xD;
          2. Be willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
          3. Greater than or equal to 18 years of age at Visit 1&#xD;
&#xD;
          4. Documentation of a CF diagnosis as evidenced by one or more clinical features&#xD;
             consistent with the CF phenotype and one or more of the following criteria:&#xD;
&#xD;
               -  Sweat chloride ≥ 60 milliequivalent (mEq)/liter by quantitative pilocarpine&#xD;
                  iontophoresis test (QPIT)&#xD;
&#xD;
               -  Two well-characterized mutations in the cystic fibrosis transmembrane conductance&#xD;
                  regulator (CFTR) gene&#xD;
&#xD;
               -  Abnormal nasal potential difference (NPD) (change in NPD in response to a low&#xD;
                  chloride solution and isoproteronol of less than -5 mV)&#xD;
&#xD;
          5. Documentation of NTM culture positive defined as follows:&#xD;
&#xD;
               -  Two positive NTM culture results from sputum (or BAL) at least 28 days apart&#xD;
                  (these are the two qualifying positive cultures)&#xD;
&#xD;
               -  Both qualifying positive culture results include M. avium complex, M. abscessus&#xD;
                  complex, or both M. avium and M. abscessus&#xD;
&#xD;
               -  Both qualifying positive culture results include the same species or subspecies&#xD;
&#xD;
               -  No cultures negative for NTM since the first of the two qualifying positive&#xD;
                  culture results&#xD;
&#xD;
          6. Current NTM species or subspecies has never been treated or previous treatment was&#xD;
             associated with clearance of NTM and completed &gt; 2 years prior to Day 1&#xD;
&#xD;
          7. Forced expiratory volume in 1 second (FEV1) ≥ 25 % of predicted value at Screening&#xD;
&#xD;
          8. Able to expectorate sputum&#xD;
&#xD;
          9. Clinically stable with no significant changes in health status within 7 days prior to&#xD;
             Day 1&#xD;
&#xD;
         10. Enrolled in the CFF Cystic Fibrosis Foundation Patient Registry (CFFPR)&#xD;
&#xD;
         11. Willing to discontinue chronic azithromycin use for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following abnormal lab values at screening:&#xD;
&#xD;
               -  Hemoglobin &lt;10g/dL&#xD;
&#xD;
               -  Platelets &lt;100,000/mm3&#xD;
&#xD;
               -  White blood cells (WBC) &lt; 4,500/mm3&#xD;
&#xD;
               -  Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl&#xD;
                  transferase (GGT), or alkaline phosphatase (ALP) ≥3 x upper limit of normal&#xD;
&#xD;
               -  Serum creatinine &gt; 2.0 mg/dl and ≥1.5 x upper limit of normal&#xD;
&#xD;
               -  Ionized calcium ≤ lower limit of normal (only performed if total calcium is ≤&#xD;
                  lower limit of normal)&#xD;
&#xD;
          2. History of solid organ or hematological transplantation&#xD;
&#xD;
          3. Use of bisphosphonates within 7 days prior to Day 1&#xD;
&#xD;
          4. Known sensitivity to gallium&#xD;
&#xD;
          5. Use of any investigational drug and/or participated in any interventional clinical&#xD;
             trial within 28 days prior to Day 1&#xD;
&#xD;
          6. In the opinion of the Investigator, features of active NTM disease are present (e.g.,&#xD;
             clinical worsening is likely due to NTM disease despite definitive treatment of&#xD;
             co-pathogens and/or acute exacerbations)&#xD;
&#xD;
          7. Undergoing treatment for NTM disease or anticipate beginning treatment within 3 months&#xD;
&#xD;
          8. Current diagnosis of osteoporosis&#xD;
&#xD;
          9. For people of childbearing potential:&#xD;
&#xD;
               -  Positive pregnancy test at Visit 1 or&#xD;
&#xD;
               -  Lactating or&#xD;
&#xD;
               -  Unwilling to practice a medically acceptable form of contraception (acceptable&#xD;
                  forms of contraception: abstinence, hormonal birth control, intrauterine device,&#xD;
                  or barrier method plus a spermicidal agent), unless surgically sterilized or&#xD;
                  postmenopausal during the study&#xD;
&#xD;
         10. For people able to father a child: unwilling to use adequate contraception (as&#xD;
             determined by the investigator) during the study&#xD;
&#xD;
         11. Has any other condition that, in the opinion of the Site Investigator/designee, would&#xD;
             preclude informed consent or assent, make study participation unsafe, complicate&#xD;
             interpretation of study outcome data, or otherwise interfere with achieving the study&#xD;
             objectives&#xD;
&#xD;
         12. New initiation of chronic therapy (greater than 21 days) within 28 days prior to the&#xD;
             Enrollment Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher H. Goss, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington, Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Braam, MIH</last_name>
    <phone>206-884-1487</phone>
    <email>lauren.braam@seattlechildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Hathorne</last_name>
      <email>hyhathorne@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alix Wilson</last_name>
      <email>wilsona@njhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noni Graham</last_name>
      <email>Noni.graham@medicine.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Britany Zeglin</last_name>
      <email>bzeglin1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Gilmore</last_name>
      <email>diana.gilmore@nationwidechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Hartigan</last_name>
      <email>elizabeth.hartigan@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Warden</last_name>
      <email>jonesash@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Keller</last_name>
      <email>Ashley.Keller@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Sweet</last_name>
      <email>julie.sweet@uvmhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Gambol</last_name>
      <email>TGambol@medicine.washington.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 1, 2020</study_first_submitted>
  <study_first_submitted_qc>March 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Chris Goss</investigator_full_name>
    <investigator_title>Professor of Medicine and Pediatrics, University of Washington</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Gallium Nitrate</keyword>
  <keyword>IV Gallium</keyword>
  <keyword>Nontuberculous mycobacterium</keyword>
  <keyword>NTM</keyword>
  <keyword>Mycobacterium abscessus</keyword>
  <keyword>mycobacterium avium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium nitrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

